FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, namely to an antibody molecule which binds mesothelin (MSLN), a multispecific antibody molecule which is specific to MSLN and to a representative of the superfamily of tumour necrosis factor receptors (TNFRSF), as well as to methods for preparing them. Also disclosed is a conjugate containing said antibody, as well as a pharmaceutical composition containing said antibody, molecule or conjugate. Invention also relates to a nucleic acid molecule coding an antibody that binds MSLN, to a nucleic acid molecule coding a multispecific antibody molecule, to a nucleic acid molecule coding domains of said antibodies, as well as to a vector and a host cell containing them.
EFFECT: invention is effective for treating cancer, wherein said cancer cells express MSLN on their cell surface.
33 cl, 4 dwg, 14 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MOLECULES BINDING MESOTHELIN AND CD137 | 2019 |
|
RU2815066C2 |
| Cys80-CONJUGATED IMMUNOGLOBULINS | 2016 |
|
RU2756101C2 |
| ANTICANCER VACCINES | 2017 |
|
RU2718663C2 |
| FULLY HUMAN MESOTHELIN ANTIBODIES AND IMMUNE EFFECTOR CELLS TARGETING MESOTHELIN | 2016 |
|
RU2748281C2 |
| IL4 RECEPTOR ANTIBODIES FOR USE IN VETERINARY SCIENCE | 2019 |
|
RU2837141C2 |
| FUSED PROTEIN CONSTRUCTS FOR COMPLEMENT-RELATED DISEASE | 2019 |
|
RU2824402C2 |
| IMPROVED ANTIGEN-BINDING RECEPTORS | 2018 |
|
RU2825816C2 |
| ANTI-IL31 ANTIBODIES FOR USE IN VETERINARY SCIENCE | 2020 |
|
RU2835543C1 |
| CHIMERIC HUMAN MESOTHELIOGEN ANTIGEN RECEPTORS AND USE THEREOF | 2014 |
|
RU2714902C2 |
| FUSION PROTEIN COMPRISING IL-12 AND ANTI-FAP ANTIBODY, AND USE THEREOF | 2021 |
|
RU2831612C1 |
